000169985 001__ 169985
000169985 005__ 20240229133702.0
000169985 0247_ $$2doi$$a10.1016/j.oraloncology.2021.105461
000169985 0247_ $$2pmid$$apmid:34304004
000169985 0247_ $$2ISSN$$a1368-8375
000169985 0247_ $$2ISSN$$a1744-7895
000169985 0247_ $$2ISSN$$a1878-0601
000169985 0247_ $$2ISSN$$a1879-0593
000169985 0247_ $$2altmetric$$aaltmetric:110464387
000169985 037__ $$aDKFZ-2021-01685
000169985 041__ $$aEnglish
000169985 082__ $$a610
000169985 1001_ $$aDrake, Virginia$$b0
000169985 245__ $$aBiologic and behavioral associations of estrogen receptor alpha positivity in head and neck squamous cell carcinoma.
000169985 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2021
000169985 3367_ $$2DRIVER$$aarticle
000169985 3367_ $$2DataCite$$aOutput Types/Journal article
000169985 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1642171554_15951
000169985 3367_ $$2BibTeX$$aARTICLE
000169985 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000169985 3367_ $$00$$2EndNote$$aJournal Article
000169985 500__ $$a2021 Oct;121:105461
000169985 520__ $$aTumor HPV status is an established independent prognostic marker for oropharynx cancer (OPC). Recent studies have reported that tumor estrogen receptor alpha (ERα) positivity is also associated with prognosis independent of HPV. Little is known about the biologic and behavioral predictors of ERα positivity in head and neck squamous cell cancer (HNSCC). We therefore explored this in a multicenter prospective cohort study.Participants with HNSCC completed a survey and provided a blood sample. Tumor samples were tested for ERα using immunohistochemistry. ERα positivity was defined as ≥1%, standardized by the American Society of Clinical Oncology/College of American Pathologists in breast cancer. Characteristics were compared with χ2 and Fisher's exact test. Odds ratios (OR) were calculated using logistic regression.Of 318 patients with HNSCC, one third had ERα positive tumors (36.2%, n = 115). Odds of ERα expression were significantly increased in those with HPV-positive tumors (OR = 27.5, 95% confidence interval[CI] 12.1-62), smaller tumors (≤T2, OR = 3.6, 95% CI 1.9-7.1), male sex (OR = 2.0, 95% CI 1.1-3.6), overweight/obesity (BMI ≥ 25, OR = 1.9, 95% CI 1.1-3.3), and those married/living with a partner (OR = 1.7, 95% CI 1.0-3.0). In a multivariate model, HPV-positivity (aOR = 27.5, 95% CI 11.4-66) and small tumor size (≤T2, aOR = 2.2, 95% CI 1.0-4.8) remained independently associated with ERα status. When restricted to OPC (n = 180), tumor HPV status (aOR = 17.1, 95% CI 2.1-137) and small tumor size (≤T2, aOR = 4.0 95% CI 1.4-11.3) remained independently associated with ERα expression.Tumor HPV status and small tumor size are independently associated with ERα expression in HNSCC.
000169985 536__ $$0G:(DE-HGF)POF4-316$$a316 - Infektionen, Entzündung und Krebs (POF4-316)$$cPOF4-316$$fPOF IV$$x0
000169985 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000169985 650_7 $$2Other$$aEstrogen receptor alpha
000169985 650_7 $$2Other$$aHead and neck neoplasms
000169985 650_7 $$2Other$$aOropharyngeal neoplasms
000169985 650_7 $$2Other$$aPapillomaviridae
000169985 650_7 $$2Other$$aTumor biomarkers
000169985 7001_ $$aBigelow, Elaine$$b1
000169985 7001_ $$aFakhry, Carole$$b2
000169985 7001_ $$aWindon, Melina$$b3
000169985 7001_ $$aRooper, Lisa M$$b4
000169985 7001_ $$aHa, Patrick$$b5
000169985 7001_ $$aMiles, Brett$$b6
000169985 7001_ $$aGourin, Christine$$b7
000169985 7001_ $$aMandal, Rajarsi$$b8
000169985 7001_ $$aMydlarz, Wojciech$$b9
000169985 7001_ $$aLondon, Nyall$$b10
000169985 7001_ $$aVosler, Peter S$$b11
000169985 7001_ $$aYavvari, Siddhartha$$b12
000169985 7001_ $$aTroy, Tanya$$b13
000169985 7001_ $$0P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aWaterboer, Tim$$b14$$udkfz
000169985 7001_ $$aEisele, David W$$b15
000169985 7001_ $$aD'Souza, Gypsyamber$$b16
000169985 773__ $$0PERI:(DE-600)2011971-9$$a10.1016/j.oraloncology.2021.105461$$gVol. 121, p. 105461 -$$p105461$$tOral oncology$$v121$$x1368-8375$$y2021
000169985 909CO $$ooai:inrepo02.dkfz.de:169985$$pVDB
000169985 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000169985 9131_ $$0G:(DE-HGF)POF4-316$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfektionen, Entzündung und Krebs$$x0
000169985 9141_ $$y2021
000169985 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-27
000169985 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-27
000169985 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-27
000169985 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-27
000169985 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-01-27
000169985 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-01-27
000169985 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-27
000169985 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-27
000169985 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-27
000169985 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-01-27
000169985 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-01-27
000169985 9201_ $$0I:(DE-He78)F020-20160331$$kF020$$lInfektionen und Krebs-Epidemiologie$$x0
000169985 9201_ $$0I:(DE-He78)F022-20160331$$kF022$$lInfektionen und Krebs-Epidemiologie$$x1
000169985 980__ $$ajournal
000169985 980__ $$aVDB
000169985 980__ $$aI:(DE-He78)F020-20160331
000169985 980__ $$aI:(DE-He78)F022-20160331
000169985 980__ $$aUNRESTRICTED